These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 13195587)

  • 1. [Experiences with 3-0-toloxy-1,2-propanediol (BYK-M 1)].
    WEBER HJ; LEHNER FH
    Schweiz Arch Neurol Psychiatr; 1954; 73(1-2):370-8. PubMed ID: 13195587
    [No Abstract]   [Full Text] [Related]  

  • 2. [3-0-Toloxy-1,2-propanediol (tolseron) in therapy of hemiplegia].
    RIGOLETTI L; MARTINI G; BOARO G
    Gazz Med Ital; 1953 Apr; 112(4):117-20. PubMed ID: 13083866
    [No Abstract]   [Full Text] [Related]  

  • 3. Metabolism of myanesin (3-(O-toloxy)-1,2-propanediol).
    RILEY RF
    J Pharmacol Exp Ther; 1950 Jul; 99(3):329-33. PubMed ID: 15437306
    [No Abstract]   [Full Text] [Related]  

  • 4. 3-0-Toloxy 1,2-propanediol in the treatment of rheumatic diseases.
    HERMANN IF; SMITH RT
    J Lancet; 1951 Jul; 71(7):271-4. PubMed ID: 14841445
    [No Abstract]   [Full Text] [Related]  

  • 5. The preparation and pharmacological properties of the acid succinate of 3-(o-toloxy)-1,2-propanediol (myanesin).
    BERGER FM; RILEY RF
    J Pharmacol Exp Ther; 1949 Jul; 96(3):269-75. PubMed ID: 18133077
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment of spastic and extrapyramidal fixed states with Byk M I].
    WALCH R; HOHEISEL HP
    Dtsch Med J; 1953 Oct; 4(19-20):503-5. PubMed ID: 13107463
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro metabolism of mephenesin, 3-o-tolyloyl-1,2-propanediol.
    MAASS AR; CAREY PL; HAMILTON RE; HEMING AE
    Proc Soc Exp Biol Med; 1960 Jan; 103():154-7. PubMed ID: 14419235
    [No Abstract]   [Full Text] [Related]  

  • 8. 3-otoloxy 1, 2 Propanediol as an adjunct in the treatment of drug addiction.
    MCLAUGHLIN JJ; SCHLAN LS
    Ill Med J; 1953 Apr; 103(4):247-9. PubMed ID: 13034288
    [No Abstract]   [Full Text] [Related]  

  • 9. Metabolism of myanesin (3-(o-tolyoxy)-1,2-propanediol).
    RILEY RF; BERGER FM
    Arch Biochem; 1949 Jan; 20(1):159. PubMed ID: 18104406
    [No Abstract]   [Full Text] [Related]  

  • 10. Rate of disappearance from the blood and distribution in tissues of 3-(orthotoloxyl)-1,2-propanediol (myanesin).
    MORRISON JL; RICHARDSON AP; WALKER HA
    Fed Proc; 1948 Mar; 7(1 Pt 1):246. PubMed ID: 18938577
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of 3-orthotoloxy-1,2-propanediol (tolserol, myanesin) upon electrogram of human cortex and subcortex.
    SPIEGEL EA; WYCIS HT
    Proc Soc Exp Biol Med; 1949 Nov; 72(2):446-8. PubMed ID: 15408350
    [No Abstract]   [Full Text] [Related]  

  • 12. [LUNESIN L.P.B].
    Arq Cir Clin Exp; 1955; 39(322):49-53. PubMed ID: 13283890
    [No Abstract]   [Full Text] [Related]  

  • 13. The determination of 3-(orthotoloxyl)-1,2-propanediol (myanesin) in body fluids and tissues, and its disappearance from the blood following intravenous injections in the dog.
    TITUS E; ULICK S; RICHARDSON AP
    J Pharmacol Exp Ther; 1948 Jun; 93(2):129-34. PubMed ID: 18865194
    [No Abstract]   [Full Text] [Related]  

  • 14. Point of action of 3-o-toloxy-1, 2-propanediol and effects of nervous system.
    FINKELMAN I
    Arch Neurol Psychiatry; 1949 Jun; 61(6):680-7. PubMed ID: 18145436
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapeutic possibilities in spasticity. Review].
    Roşianu C
    Neurol Psihiatr Neurochir; 1971; 16(1):59-70. PubMed ID: 4253575
    [No Abstract]   [Full Text] [Related]  

  • 16. Tics, tremors and other movement disorders in childhood.
    Blackburn J; Parnes M
    Curr Probl Pediatr Adolesc Health Care; 2021 Mar; 51(3):100983. PubMed ID: 33832853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Movement disorders in multiple sclerosis.
    Oakes PK; Srivatsal SR; Davis MY; Samii A
    Phys Med Rehabil Clin N Am; 2013 Nov; 24(4):639-51. PubMed ID: 24314682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [On the hemolytic action of mephenesin and of 3-(p.propionyl-o.methoxy-phenoxy)-1,2-propanediol].
    Coppi G
    Boll Soc Ital Biol Sper; 1964 Sep; 40(18):1125-7. PubMed ID: 5876957
    [No Abstract]   [Full Text] [Related]  

  • 19. Site of action of 2, 2-diethyl-1,3-propanediol (prenderol) on the central nervous system.
    FUNDERBURK WH; UNNA KR
    J Pharmacol Exp Ther; 1953 Mar; 107(3):344-55. PubMed ID: 13035673
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of conventional and sensory-enhanced physiotherapy on disability of Parkinson's disease patients.
    Dam M; Tonin P; Casson S; Bracco F; Piron L; Pizzolato G; Battistin L
    Adv Neurol; 1996; 69():551-5. PubMed ID: 8615180
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.